ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.27
0.00%
US Tech 100
20,696.40
0.80%
S&P 500
5,955.25
-0.47%
US Dollar vs CAD
1.43333
0.22%
Bitcoin
88,625.27
-0.01%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE

  6. Novartis AG (NVS) Share Price

Novartis AG

Novartis AG (NVS)

Novartis CDR
109.62
0.40
(0.37%)
Closed February 25 3:00PM
Delayed by 15 minutes
109.51
-0.11
( -0.10% )
Pre Market: 5:37AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
109.51
Bid
-
Ask
-
Volume
7,268
0.00 Day's Range 0.00
92.35 52 Week Range 120.92
Market Cap
216.292B
Previous Close
109.62
Open
-
Last Trade
1
@
109.53
Last Trade Time
05:19:57
Financial Volume
-
VWAP
-
Average Volume (3m)
1,679,269
Shares Outstanding
1,975,089,248
Dividend Yield
-
PE Ratio
18.39
Earnings Per Share (EPS)
6.05
Revenue
51.72B
Net Profit
11.94B

About Novartis AG

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, ca... Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.novartis.com
Headquarters
Basel, Che
Founded
-
Novartis AG is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker NVS. The last closing price for Novartis was US$109.62. Over the last year, Novartis shares have traded in a share price range of US$ 92.35 to US$ 120.92.

Novartis currently has 1,975,089,248 shares outstanding. The market capitalization of Novartis is US$216.51 billion. Novartis has a price to earnings ratio (PE ratio) of 18.39.

Ask ADVFN Intelligence (AI)

Novartis (NVS) Options Flow Summary

NVS Options Flow

Overall Flow

Bearish

Net Premium

-7M

Calls / Puts

17,59%

Buys / Sells

108,62%

OTM / ITM

10,43%

Sweeps Ratio

0,00%

NVS Latest News

More News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
December 30 2024
NVS (0.37%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
November 25 2024
NVS (0.37%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 29 2024
NVS (0.37%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
October 29 2024
NVS (0.37%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
13.052.86492579373106.46112.98106.12505777108.89561951DR
46.556.36169386169102.96112.98102.6752345556106.98084168DR
127.447.28911531302102.07112.9896.231679269103.02842205DR
26-9.18-7.73443424046118.69120.9296.231349739107.06018274DR
524.934.71409447313104.58120.9292.351384364104.80600254DR
15622.5225.888033107386.99120.9274.09177384394.204791DR
26020.9223.614403431588.59120.9269.1191367790.7858515DR

NVS - Frequently Asked Questions (FAQ)

What is the current Novartis share price?
The current share price of Novartis is US$ 109.51
How many Novartis shares are in issue?
Novartis has 1,975,089,248 shares in issue
What is the market cap of Novartis?
The market capitalisation of Novartis is USD 216.51B
What is the 1 year trading range for Novartis share price?
Novartis has traded in the range of US$ 92.35 to US$ 120.92 during the past year
What is the PE ratio of Novartis?
The price to earnings ratio of Novartis is 18.39
What is the cash to sales ratio of Novartis?
The cash to sales ratio of Novartis is 4.24
What is the reporting currency for Novartis?
Novartis reports financial results in USD
What is the latest annual turnover for Novartis?
The latest annual turnover of Novartis is USD 51.72B
What is the latest annual profit for Novartis?
The latest annual profit of Novartis is USD 11.94B
What is the registered address of Novartis?
The registered address for Novartis is PO BOX, BASEL, 4002
What is the Novartis website address?
The website address for Novartis is www.novartis.com
Which industry sector does Novartis operate in?
Novartis operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIOPioneer Municipal High Income Opportunities Fund Inc
US$ 18.99
(56.81%)
41
HTBHomeTrust Bancshares Inc
US$ 37.99
(49.98%)
6
MOVMovado Group Inc
US$ 28.99
(44.09%)
16
ACAssociated Capital Group Inc
US$ 50.00
(34.16%)
477
BYByline Bancorp Inc
US$ 37.99
(33.16%)
3
WEAWestern Asset Premier Bond Fund
US$ 5.01
(-54.08%)
2
HGTYHagerty Inc
US$ 5.22
(-48.42%)
21
CODICompass Diversified
US$ 11.12
(-46.28%)
3
MUJBlackRock MuniHoldings New Jersey Quality Fund Inc
US$ 7.01
(-39.72%)
1
GFNew Germany Fund Inc
US$ 6.01
(-33.59%)
5
BABAAlibaba Group Holding Limited
US$ 139.97
(4.45%)
707.22k
QBTSD Wave Quantum Inc
US$ 6.26
(5.74%)
631.74k
NIONIO Inc
US$ 4.40
(3.04%)
588.65k
SESSES AI Corporation
US$ 0.8906
(6.23%)
562.44k
BBAIBigBear ai Holdings Inc
US$ 5.91
(5.54%)
476.75k

NVS Discussion

View Posts
Monksdream Monksdream 6 months ago
NVS new 52=high
👍️0
Monksdream Monksdream 7 months ago
NVS new 52=week high
👍️0
Monksdream Monksdream 8 months ago
NVS new 52 week high
👍️0
avxl_going_long avxl_going_long 10 months ago
https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm
👍️0
da_stock_analyst da_stock_analyst 10 months ago
Radiopharma stocks higher as sector welcomes the latest M&A deal https://seekingalpha.com/news/4099035-novartis-mariana-oncology-deal-drives-radiopharma ..Shares of radiopharma companies spiked as investors welcomed the latest M&A deal to hit the sector. $NVS $CATX $CLRB $CASI $LNTH and ATNM. for more info click here https://shorturl.at/hoU47
👍️0
Monksdream Monksdream 10 months ago
NVS 10Q due 4/23
👍️0
Monksdream Monksdream 1 year ago
NVS new 52 week high
👍️0
Monksdream Monksdream 1 year ago
NVS new 52 week high
👍️0
Monksdream Monksdream 1 year ago
NVS new 52 week high
👍️0
1jas 1jas 2 years ago
have you seen yesterday that enzolytics pharm announced that they now have a CURE for hiv/aids called clone3.?
👍️0
ernie44 ernie44 2 years ago
its a home run ---or is it just the runs

https://apis.mail.yahoo.com/ws/v3/mailboxes/@.id==VjN-cV7LhC8rx0EcG5-z9RhWgRsQvGZwTs2qwUxoYR9UStj84lOVi7ZIeMO8HFiplsA65ZbE_cF9gB9A2TSm5APqCg/messages/@.id==AA43g3BH-2gCZMlFEQgiCNhLPmU/content/parts/@.id==2/thumbnail?appid=YMailNorrin&downloadWhenThumbnailFails=true&pid=2
👍️0
awesomed007 awesomed007 2 years ago
https://www.prnewswire.com/news-releases/dtx-pharma-announces-acquisition-by-novartis-301877974.html. I have cmt. Getting closer to 1st fda approved treatment, hopeful!!!
👍️0
subslover subslover 3 years ago
Former Head of Novartis Respiratory and Allergy Medicine to Advise Clinical Stage Stem Cell Company on COVID-19 and COPD Programs
https://www.otcmarkets.com/stock/TSOI/news/story?e&id=2224788
👍️0
FACT-MASTER FACT-MASTER 3 years ago
https://www.novartis.com/news/media-releases/new-novartis-data-demonstrate-only-kisqali-offers-more-life-first-line-setting-postmenopausal-hrher2-advanced-breast-cancer-patients
👍️0
FACT-MASTER FACT-MASTER 3 years ago
https://www.novartis.com/news/media-releases/novartis-kymriah-receives-ec-approval-first-car-t-cell-therapy-adults-relapsed-or-refractory-follicular-lymphoma
👍️0
FACT-MASTER FACT-MASTER 3 years ago
Novartis also has a collaboration agreement with TScan Therapeutics for development of TCR-T cancer technology, one of the latest and promising therapeutics that could accompany CAR-T.

https://ir.tscan.com/news-releases/news-release-details/tscan-announces-collaboration-novartis-discovery-and-development

TScan entering clinical Phase 1 in 1H 2022.
👍️0
DewDiligence DewDiligence 3 years ago
FDA approves NVS’ Pluvicto*, a radioligand for CRPC:

https://www.globenewswire.com/news-release/2022/03/23/2408996/0/en/Novartis-PluvictoTM-approved-by-FDA-as-first-targeted-radioligand-therapy-for-treatment-of-progressive-PSMA-positive-metastatic-castration-resistant-prostate-cancer.html

NVS obtained this agent from the ECYT buyout in 2018 (#msg-144295734).

*f/k/a 177Lu-PSMA-617.
👍️0
DewDiligence DewDiligence 3 years ago
FDA approves NVS’ Leqvio—(inclisiran)—for lowering LDL-C:

https://www.prnewswire.com/news-releases/fda-approves-novartis-leqvio-inclisiran-first-in-class-sirna-to-lower-cholesterol-and-keep-it-low-with-two-doses-a-year-301450125.html

NVS initially received a CRL from the FDA in late 2020 due to the FDA’s inability to conduct an inspection of the Leqvio’s manufacturing site in Italy (#msg-160327185).

Leqvio is a siRNA dosed semiannually (except for the 3-month interval between the first two doses). NVS picked up this drug when it acquired MDCO in Nov 2019 (#msg-152458295).

ALNY, which will get a 10-20% royalty on global sales, discovered Inclisiran and out-licensed it to MDCO in 2013 (#msg-84151150); with the benefit of hindsight we can say that MDCO clearly got the better of ALNY in this deal.

Leqvio was approved in the EI in late 2020 (https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-leqvio-inclisiran-first-class-sirna-lower-cholesterol-two-doses-year ).
👍️0
DewDiligence DewDiligence 3 years ago
NVS plans $15B share buybacks through 2023—exhausting ~70% of the proceeds from the recent sale of Roche shares:

https://finance.yahoo.com/news/novartis-initiates-usd-15-billion-060000184.html

This might be one reason XBI was down today.
👍️0
ht1 ht1 4 years ago
Novartis should invest in mRNA medicine and pair up with companies like Regen Biopharma to speed up this process. Perhaps an outright purchase of this start up company. This will ensure competing with likes of Pfizer and Moderna.
👍️0
DewDiligence DewDiligence 4 years ago
FDA_advisory_panel_endorses Entresto for_heart_failure_in_12-1_vote:

https://www.prnewswire.com/news-releases/novartis-announces-positive-fda-advisory-committee-recommendation-for-use-of-entresto-to-treat-patients-with-hfpef-301193607.html
👍️0
dshade dshade 4 years ago
good news today - Novartis Says Asciminib Showed Superior MMR Rate to Bosulif in Leukemia Trial
December 08 2020 - 11:00AM
Dow Jones News

By Michael Dabaie


Novartis AG said asciminib showed superior major molecular response rate to Bosulif in a chronic myeloid leukemia trial.

The company said results from a Phase III study demonstrate that at 24 weeks, asciminib nearly doubled the major molecular response rate compared with Bosulif in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibitor therapies.

The data were presented at a late-breaking abstracts session during the 62nd American Society of Hematology Annual Meeting & Exposition, Novartis said.

In the trial, 233 patients were randomized to receive asciminib 40 mg twice daily or Bosulif 500 mg once a day.

Novartis said the U.S. Food and Drug Administration granted Fast Track designation for asciminib. The company said it plans submission to U.S. and EU health authorities in the first half of 2021.
👍️0
dshade dshade 4 years ago
good news today
👍️0
DewDiligence DewDiligence 4 years ago
CHMP approves NVS’ Leqvio (inclisiran) for hypercholesterolemia or mixed dyslipidemia:

https://www.globenewswire.com/news-release/2020/10/16/2109800/0/en/Novartis-receives-positive-CHMP-opinion-for-Leqvio-inclisiran-a-potential-first-in-class-siRNA-for-the-treatment-of-high-cholesterol.html

Rubber-stamping by the European Commission will follow in 2-3 months.
👍️0
DewDiligence DewDiligence 5 years ago
NVS/GMAB—FDA approves Kesimpta—(subcutaneous ofatumumab)—for MS:

https://finance.yahoo.com/news/u-fda-approves-kesimpta-ofatumumab-173300452.html
https://t.co/9AOLIf7Qln?amp=1

NVS acquired the commercial rights to ofatumumab from GSK, and NVS will pay GSK a tiered royalty up to 12% on worldwide sales of Kesimpta (#msg-116391951).

Ofatumumab, administered via IV, was FDA-approved for CLL under the brand name, Arzerra in 2009 (#msg-42935958).
👍️0
DewDiligence DewDiligence 5 years ago
Ofatumumab PFUFA delayed 3mo—>Sep 2020 for MS indication:

https://www.globenewswire.com/news-release/2020/06/02/2042559/0/en/Novartis-provides-update-on-FDA-review-of-ofatumumab-a-self-administered-targeted-B-cell-therapy-for-patients-with-relapsing-multiple-sclerosis.html

The PR does not cite a reason for the delay.

NVS acquired Ofatumumab’s commercial rights in MS from GSK in a 2015 transaction involving a $500M up-front payment by NVS (#msg-116391951).
👍️0
fung_derf fung_derf 5 years ago
What am I missing here? Why is no one talking about Novartis for their hydroxychloroquine?
👍️0
DewDiligence DewDiligence 5 years ago
NVS concedes Beovu has new safety issue:

https://www.brolucizumab.info/ Novartis has now completed its review of these post-marketing safety case reports… Based on internal and SRC assessment, it was concluded that there is a confirmed safety signal of rare adverse events of “retinal vasculitis and/or retinal vascular occlusion with or without presence of intraocular inflammation that may result in severe vision loss.”

Based on this review, Novartis has initiated a safety information update to Beovu prescribing information worldwide. Currently approved prescribing information includes intraocular inflammations, visual acuity decrease (including blindness) and retinal artery occlusion as separate terms. We will work with regulatory authorities to finalize the prescribing information update.

In addition, we are working with our data monitoring committees and informing investigators of ongoing clinical trials. Novartis-sponsored studies will be amended so that protocols, Informed Consent Forms and Investigator Brochures reflect this new safety information. Investigators are also being informed to re-consent patients.
👍️0
Maddog 112 Maddog 112 5 years ago
Ok thank you
👍️0
DewDiligence DewDiligence 5 years ago
It won't have any effect at all on the share price. It's a goodwill gesture and it's the right thing to do morally.
👍️0
Maddog 112 Maddog 112 5 years ago
How much will this affect the stock price 160 mil pills at 4$ is a lot of money
👍️0
DewDiligence DewDiligence 5 years ago
Yes—that was announced on Friday: #msg-154462215.
👍️0
Maddog 112 Maddog 112 5 years ago
Is it true NVS to supply 160 mil chloroquine pills to America to help fight corona virus
👍️0
DewDiligence DewDiligence 5 years ago
More on the same story (Beovu safety):

https://endpts.com/novartis-plans-to-wrestle-eylea-market-share-take-a-hit-as-beovu-is-linked-to-safety-concerns/
👍️0
DewDiligence DewDiligence 5 years ago
Acceptance of a BLA/NDA application for review doesn’t generally move the needle for a company as large as NVS unless the FDA grants a priority review when investors expected a standard review, which wasn’t the case here.
👍️0
Ecomike Ecomike 5 years ago
And so this got ignored.

https://ih.advfn.com/stock-market/NYSE/novartis-NVS/stock-news/81828953/novartis-fda-ema-accept-filings-for-ofatumumab-i?xref=ff_sidebar_quote
👍️0
DewDiligence DewDiligence 5 years ago
The cause is a safety update re Beovu (the recently approved drug for AMD):

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153989588

https://www.statnews.com/2020/02/24/safety-concerns-regarding-novartiss-new-eye-drug-boost-regeneron-stock/
👍️0
Ecomike Ecomike 5 years ago
5.5% drop on a biotech drug firm like NVS 8 days before the dividend date looks way over done to me with Biotechs in favor and nothing but Good news today and recently on NVS.

Panic selling seems way over done. But then again panics are like that.

You see any bad news at all on NVS I missed?
👍️0
DewDiligence DewDiligence 5 years ago
NVS 12/5/19 R&D Day slides:

https://www.novartis.com/sites/www.novartis.com/files/2019-12-05-novartis-r-d-day-investor-presentation.pdf
👍️0
DewDiligence DewDiligence 5 years ago
NVS PR in conjunction with R&D Day investor webcast:

https://www.globenewswire.com/news-release/2019/12/05/1956569/0/en/Novartis-expects-to-sustain-long-term-growth-with-a-robust-pipeline-of-25-potential-blockbusters-highlighted-at-R-D-Day.html
👍️0
elotto777 elotto777 5 years ago
These shares are a BUY - Up and Away is how we would describe this company
READ REPORT HERE https://pennystocks.news/biotech-mega-merger-novartis-buys-medicines-co-9-7-billion-deal/
👍️0
DewDiligence DewDiligence 5 years ago
NVS acquires MDCO for $85/sh cash—a 64% premium to MDCO’s closing price on 11/15/19, the day before serious buyout rumors began circulating:

https://www.globenewswire.com/news-release/2019/11/24/1951667/0/en/Novartis-to-acquire-The-Medicines-Company-for-USD-9-7-bn-adding-inclisiran-a-potentially-transformational-investigational-cholesterol-lowering-therapy-to-address-leading-global-cau.html

https://www.novartis.com/sites/www.novartis.com/files/novartis-mdco-acquisition.pdf (CC slides)

The nominal deal value is $9.7B (on a fully-diluted basis). There is no CVR.
👍️0
DewDiligence DewDiligence 5 years ago
CHMP approves NVS’ Mayzent for SPMS:

https://www.globenewswire.com/news-release/2019/11/15/1947899/0/en/Novartis-receives-positive-CHMP-opinion-for-Mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-SPMS.html
👍️0
whytestocks whytestocks 5 years ago
News: $NVS ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG - NVS

NEW YORK, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business in...

Read the whole news NVS - ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG - NVS
👍️0
DewDiligence DewDiligence 5 years ago
FDA approves NVS’ Beovu—(a/k/a brolucizumab/RTH258) for wet AMD—3mo dosing interval after the loading phase:

https://www.globenewswire.com/news-release/2019/10/08/1926199/0/en/Novartis-receives-FDA-approval-for-Beovu-offering-wet-AMD-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept.html

US list price will be $1,850 per vial—inline with main competitor Eylea—according to Vantage (https://www.globenewswire.com/news-release/2019/10/08/1926199/0/en/Novartis-receives-FDA-approval-for-Beovu-offering-wet-AMD-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept.html ).
👍️0
DewDiligence DewDiligence 6 years ago
Here's the cause of today's sell-off:

https://www.wsj.com/articles/fda-says-data-manipulation-occurred-in-trials-of-world-s-priciest-drug-11565116881
👍️0
Ecomike Ecomike 6 years ago
Any clue what too the air out this one this afternoon?

I see no news yet to justify the swan dive mid day today.
👍️0
Ecomike Ecomike 6 years ago
I would love to hear more about that whole story?
👍️0
biopharm biopharm 6 years ago
Novartis been researching PS Phosphatidylserine targeting ?

Drug: MBG453
MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
...
...

Dew, what do you think of the rumors swirling around PS Targeting drugs? Novartis has been swirling all around PS Targeting ever since they brought on Glen Dranoff from Dana Farber ...

Now with Dana Farber Gordon Freeman and Clive Wood enhancing patents that they collaborated on ....patents surrounding PS Targeting are key
👍️0
PennyStock Alert PennyStock Alert 6 years ago
Green after hours trading
👍️0

Your Recent History

NYSE
NVS
Novartis
LSE
WSIL
Wt Core Silver
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads